Similar articles

• Dermatological uses of high-dose intravenous immunoglobulin.

  Jolles S, Hughes J, Whittaker S. Jolles S, et al. Arch Dermatol. 1998 Jan;134(1):80-6. doi: 10.1001/archderm.134.1.80. Arch Dermatol. 1998. PMID: 9449914 Review.
• Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience.

  Wetter DA, Davis MD, Yiannias JA, Gibson LE, Dahl MV, el-Azhary RA, Bruce AJ, Lookingbill DP, Ahmed I, Schroeter AL, Pittelkow MR. Wetter DA, et al. Mayo Clin Proc. 2005 Jan;80(1):41-7. doi: 10.1016/S0025-6196(11)62956-X. Mayo Clin Proc. 2005. PMID: 15667028
• Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis.

  Luzi G, Diamanti AP, Germano V, Laganà B, Di Rosa R, Salemi S, Stoppacciaro A, D'Amelio R. Luzi G, et al. Clin Immunol. 2007 Nov;125(2):127-30. doi: 10.1016/j.clim.2007.07.009. Epub 2007 Aug 27. Clin Immunol. 2007. PMID: 17720626
• Plasma exchanges in the treatment of skin disease.

  Roujeau JC, Fabre M, Noel L. Roujeau JC, et al. Int J Artif Organs. 1982 Jul;5(4):257-60. Int J Artif Organs. 1982. PMID: 6126439 Review. No abstract available.
• Intravenous immunoglobulins in dermatology. Part 2: clinical indications and outcomes.

  Forbat E, Ali FR, Al-Niaimi F. Forbat E, et al. Clin Exp Dermatol. 2018 Aug;43(6):659-666. doi: 10.1111/ced.13552. Epub 2018 May 17. Clin Exp Dermatol. 2018. PMID: 29774587 Review.